Lifeboat Foundation: Safeguarding Humanity
Toggle light / dark theme

Blog

Category: biotech/medical – Page 1,044

“It is not enough to study brain connectivity with one single method, or even two,” says HBP Scientific Director and author of the Science article Katrin Amunts, who leads the Institute of Neuroscience and Medicine (INM-1) at Forschungszentrum Jülich and the C. & O. Vogt Institute of Brain Research at the University Hospital Düsseldorf. “The connectome is nested at multiple levels. To understand its structure, we need to look at several spatial scales at once by combining different experimental methods in a multi-scale approach and by integrating the obtained data into multilevel atlases such as the Julich Brain Atlas that we have developed.”

Markus Axer from Forschungszentrum Jülich and the Physics Department of the University of Wuppertal, who is the first author of the Science article, has together with his team at INM-1 developed a unique method called 3D Polarised Light Imaging (3D-PLI) to visualise nerve fibres at microscopic resolution. They trace the three-dimensional courses of fibres across serial brain sections with the aim of developing a 3D fibre atlas of the entire human brain.

Together with other HBP researchers from Neurospin in France and the University of Florence in Italy, Axer and his team have recently imaged the same tissue block from a human hippocampus using several different methods: anatomical and diffusion magnetic resonance imaging (aMRI and dMRI), two-photon fluorescence microscopy (TPFM) and 3D-PLI, respectively.

Read more | >

A novel brain-computer interface developed by a New York-based company called Synchron was just used to help a paralyzed patient send messages using their Apple device for the very first time. It’s a massive step up in an industry that has increasingly reported progress, which suggests that interfacing our minds with consumer devices could happen a lot sooner than some of us bargained for.

Brain-computer devices eavesdrop on brainwaves and convert these into commands. More or less the same neural signals that healthy people use to instruct their muscle fibers to twitch and enact a movement like walking or grasping an object can be used to command a robotic arm or move a cursor on a computer screen. It really is a phenomenal and game-changing piece of technology, with obvious benefits for those who are completely paralyzed and have few if any means of communicating with the outside world.

This type of technology is not exactly new. Scientists have been experimenting with brain-computer interfaces for decades, but it’s been in the last couple of years or so that we’ve actually come to see tremendous progress. Even Elon Musk has jumped on this bandwagon, founding a company called Neuralink with the ultimate goal of developing technology that allows people to transmit and receive information between their brain and a computer wirelessly — essentially connecting the human mind to devices. The idea is for anyone to be able to use this technology, even normal, healthy people, who want to augment their abilities by interfacing with machines. In 2021, Neuralink released a video of a monkey with an implanted Neuralink device playing pong, and the company wants to start clinical trials with humans soon.

Read more | >

With inherited gene mutations from both parents, a woman in Spain is battling with 12 tumors in her body.

As stated by the Spanish National Cancer Research Centre (CNIO), the woman first developed a tumor when still a baby and other tumors followed it within five years. 36 year-old-patient has developed twelve tumors, at least five of them malignant in her life. Each one has been of a unique kind and has affected a different area of the body.

“We still don’t understand how this individual could have formed during the embryonic stage, nor could have overcome all these pathologies,” says Marcos Malumbres, director of the Cell Division and Cancer Group at the Spanish National Cancer Research Centre (CNIO).

Read more | >

For the last few decades, battery research has largely focused on rechargeable lithium-ion batteries, which are used in everything from electric cars to portable electronics and have improved dramatically in terms of affordability and capacity. But nonrechargeable batteries have seen little improvement during that time, despite their crucial role in many important uses such as implantable medical devices like pacemakers.

Now, researchers at MIT have come up with a way to improve the energy density of these nonrechargeable, or “primary,” batteries. They say it could enable up to a 50% increase in useful lifetime, or a corresponding decrease in size and weight for a given amount of power or energy capacity, while also improving safety, with little or no increase in cost.

The new findings, which involve substituting the conventionally inactive battery electrolyte with a material that is active for energy delivery, are reported today in the journal Proceedings of the National Academy of Sciences, in a paper by MIT Kavanaugh Postdoctoral Fellow Haining Gao, graduate student Alejandro Sevilla, associate professor of mechanical engineering Betar Gallant, and four others at MIT and Caltech.

Read more | >

New foundation aims for scientific and rhetorical value – and to run the debug cycle for longevity research.

The Longevity Investors Conference is quickly turning into one of the highlights in the longevity calendar, and we were delighted to be able to interview some of the speakers in a few ‘backstage’ moments.

Held in the exclusive location of Gstaad in Switzerland, The Longevity Investors Conference (LIC) is the world’s leading and most private longevity-focused investors-only conference. Providing relevant insights into the fast-growing field of longevity, the conference also offers expert education and investment opportunities, as well as fostering excellent networking opportunities. Dr Aubrey de Grey was in Gstaad to address the conference on rejuvenation biotechnology as well as being part of a panel discussing where crypto meets longevity.

Visit Longevity. Technology — https://bit.ly/3PwtH8Y

Follow Longevity. Technology on:
Twitter — https://bit.ly/3AMIXuq.
Facebook — https://bit.ly/3z8H1v5
Instagram — https://bit.ly/3IDvVRX
Linkedin — https://bit.ly/3yIfDmf

Read more | >

Genetic engineering is a rapidly progressing scientific discipline, with tremendous current application and future potential. It’s a bit dizzying for a science communicator who is not directly involved in genetics research to keep up. I do have some graduate level training in genetics so at least I understand the language enough to try to translate the latest research for a general audience.

Many readers have by now heard of CRISPR – a powerful method of altering or silencing genes that brings down the cost and complexity so that almost any genetics lab can use this technique. CRISPR is actually just the latest of several powerful gene-altering techniques, such as TALEN. CRISPR is essentially a way to target a specific sequence of the DNA, and then deliver a package which does something, like splice the DNA. But you also need to target the correct cells. In a petri dish, this is simple. But in living organism, this is a huge challenge. We have developed several viral vectors that can be targeted to specific cell types in order to deliver the CRIPR (or TALEN), which then targets the specific DNA.

Now I would like to present a different technique I have not previously written about here – alternative splicing. A recent study presents what seems like a significant advance in this technology, so it’s a good time to review it. “Alternative splicing” refers to a natural phenomenon of genetics. Genes are composed of introns and exons. I always thought the nomenclature was counterintuitive, but the exons are actually the part of the gene that gets expressed into a protein. The introns are the part that is not expressed, so they are cut out of the gene when it is being converted into mRNA, and the exons are stitched together to form the sequence that is translated into a protein. Alternative splicing refers to the fact that the way in which the introns are removed and the exons stitched together can vary, creating alternative forms of the resulting protein.

Read more | >

A team of researchers from Korea University, Ajou University and Hanyang University, all in the Republic of Korea, has created a tiny aquabot propelled by fins made of a porous hydrogel imbued with nanoparticles. In their paper published in the journal Science Robotics, the group describes how the hydrogel works to power a tiny boat and reveals how much voltage was required.

Scientists and engineers have been working for several years to build tiny, soft robots for use in and have found that hydrogels are quite suitable for the task. Unfortunately, such materials also have undesirable characteristics, most notably, poor electro-connectivity. In this new effort, the researchers took a new approach to making hydrogels more amenable for use with electricity as a —adding conductive nanoparticles.

The work involved adding a small number of nanoparticles to a part of a porous hydrogel which they then used as a wrinkled nanomembrane electrode (WNE) . Adding the nanoparticles allowed the hydrogel to conduct electricity in a reliable way. Testing showed the actuator could be powered with as little as 3 volts of electricity. The researchers then fashioned two of the actuators into finlike shapes and attached them to a tiny plastic body. Electronics added to the body controlled the electricity sent to the fins. The resulting robot had a water bug appearance, floating on the surface of the water in a tank.

Read more | >

A Ludwig Cancer Research study has developed a novel nanotechnology that triggers potent therapeutic anti-tumor immune responses and demonstrated its efficacy in mouse models of multiple cancers. Led by Co-director Ralph Weichselbaum, investigator Wenbin Lin and postdoctoral researcher Kaiting Yang at the Ludwig Center at Chicago, the study describes the synthesis, mechanism of action and preclinical assessment of the nanoparticle, which is loaded with a drug that activates a protein central to the efficient induction of anti-cancer immunity. The study, which overcomes significant technical barriers to targeting that protein-;stimulator of interferon genes, or STING-;for cancer therapy, appears in the current issue of Nature Nanotechnology.

“The nanoparticles developed by the Lin lab release a drug that targets macrophages and can activate potent antitumor immune responses that extend the survival of mice bearing a variety of tumors,” said Chicago Center Co-director Weichselbaum. “When used in combination with radiotherapy and immunotherapy, they even help control ‘cold tumors’ that are otherwise almost completely impervious to immune attack.”

STING is part of cellular sensing system for DNA fragments, which are generated by infection or cancer treatments that damage DNA, like radiotherapy and some chemotherapies. Its activation promotes inflammation and drives immune cells like macrophages and dendritic cells to process and present cancer antigens to T cells, helping to stimulate and direct the immune assault on tumors. Though STING is a prized target for drug development, the drug-like molecules that can activate the molecular sensor-;known as cyclic dinucleotides (CDNs)-;have been plagued by issues of poor bioavailability, low stability and high toxicity in the absence of any means to target them specifically to tumors.

Read more | >